In-Med Prognostics, established in 2018, develops AI-powered brain imaging software to aid assessment and early detection of neurological disorders including dementia, Alzheimer’s disease, and Parkinson’s disease. Its product suite includes NeuroFlo (a neurology workflow platform), NeuroShield (an AI app that provides ethnicity-specific volumetric brain analysis reports within 20 minutes), and VivoShield Sports (an AI platform for sports-medicine insights). The company has tie-ups with diagnostics providers and hospitals in India such as Aarthi Scans, Scansworld, Gujarat Scans, Nanavati Hospital, and Kauvery Hospital. It maintains offices in India and also operates in Australia and the United States. In-Med recently secured $2.13 million in investment from Exxora and other angel investors. The company plans to use the funds to broaden its product portfolio and expand its reach into global markets, and is establishing a presence in Africa.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2022